-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Parkman Healthcare Partners LLC Raises Stock Holdings in Imago BioSciences, Inc. (NASDAQ:IMGO)
Parkman Healthcare Partners LLC Raises Stock Holdings in Imago BioSciences, Inc. (NASDAQ:IMGO)
Parkman Healthcare Partners LLC lifted its holdings in shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) by 27.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,751 shares of the company's stock after purchasing an additional 29,751 shares during the quarter. Parkman Healthcare Partners LLC's holdings in Imago BioSciences were worth $2,693,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Imago BioSciences by 68.8% during the first quarter. Vanguard Group Inc. now owns 793,101 shares of the company's stock worth $15,283,000 after purchasing an additional 323,376 shares in the last quarter. BlackRock Inc. lifted its position in Imago BioSciences by 146.2% in the 1st quarter. BlackRock Inc. now owns 3,290,894 shares of the company's stock worth $63,415,000 after buying an additional 1,954,112 shares during the last quarter. Rhumbline Advisers bought a new stake in Imago BioSciences in the 1st quarter worth approximately $345,000. Metropolitan Life Insurance Co NY bought a new stake in Imago BioSciences in the 1st quarter worth approximately $28,000. Finally, MetLife Investment Management LLC bought a new stake in Imago BioSciences in the first quarter valued at approximately $242,000. Hedge funds and other institutional investors own 99.50% of the company's stock.
Get Imago BioSciences alerts:Insider Transactions at Imago BioSciences
In other news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at $2,888,382.69. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 8,168 shares of company stock valued at $155,402. Insiders own 14.90% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reduced their target price on Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, August 16th.Imago BioSciences Price Performance
NASDAQ IMGO opened at $16.77 on Friday. Imago BioSciences, Inc. has a 12 month low of $11.56 and a 12 month high of $30.21. The stock's fifty day moving average price is $16.32 and its 200-day moving average price is $17.09.
About Imago BioSciences
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
See Also
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
Want to see what other hedge funds are holding IMGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating).
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Parkman Healthcare Partners LLC lifted its holdings in shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) by 27.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,751 shares of the company's stock after purchasing an additional 29,751 shares during the quarter. Parkman Healthcare Partners LLC's holdings in Imago BioSciences were worth $2,693,000 at the end of the most recent quarter.
根据Parkman Healthcare Partners LLC提交给美国证券交易委员会的最新Form 13F文件,该公司在第一季度增持了Imago BioSciences,Inc.(纳斯达克代码:IMGO-GET评级)的股票27.0%。该机构投资者在本季度额外购买了29,751股后,持有该公司139,751股股票。截至最近一个季度末,Parkman Healthcare Partners LLC持有的Imago BioSciences股份价值2,693,000美元。
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Imago BioSciences by 68.8% during the first quarter. Vanguard Group Inc. now owns 793,101 shares of the company's stock worth $15,283,000 after purchasing an additional 323,376 shares in the last quarter. BlackRock Inc. lifted its position in Imago BioSciences by 146.2% in the 1st quarter. BlackRock Inc. now owns 3,290,894 shares of the company's stock worth $63,415,000 after buying an additional 1,954,112 shares during the last quarter. Rhumbline Advisers bought a new stake in Imago BioSciences in the 1st quarter worth approximately $345,000. Metropolitan Life Insurance Co NY bought a new stake in Imago BioSciences in the 1st quarter worth approximately $28,000. Finally, MetLife Investment Management LLC bought a new stake in Imago BioSciences in the first quarter valued at approximately $242,000. Hedge funds and other institutional investors own 99.50% of the company's stock.
其他几家对冲基金和其他机构投资者最近也调整了对该公司的持股。先锋集团(Vanguard Group Inc.)在第一季度增持了Imago BioSciences股票68.8%。先锋集团目前持有793,101股该公司股票,价值15,283,000美元,上个季度又购买了323,376股。第一季度,贝莱德公司将其在Imago BioSciences的地位提升了146.2%。贝莱德股份有限公司在上个季度增持了1,954,112股后,目前持有该公司3,290,894股股票,价值63,415,000美元。Rhumbline Advisers在第一季度购买了Imago BioSciences的新股份,价值约34.5万美元。纽约大都会人寿保险公司在第一季度购买了Imago BioSciences的新股份,价值约2.8万美元。最后,大都会人寿投资管理有限责任公司在第一季度购买了Imago BioSciences的新股份,价值约为242,000美元。对冲基金和其他机构投资者持有该公司99.50%的股票。
Insider Transactions at Imago BioSciences
Imago BioSciences的内幕交易
In other news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction on Monday, August 15th. The stock was sold at an average price of $19.41, for a total value of $108,657.18. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at $2,888,382.69. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 8,168 shares of company stock valued at $155,402. Insiders own 14.90% of the company's stock.
其他消息,内部人士珍妮弗·佩佩在8月15日(星期一)的一次交易中出售了5598股该股。这只股票的平均售价为19.41美元,总价值为108,657.18美元。出售后,这位内部人士现在直接持有该公司148,809股股票,价值2,888,382.69美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过这个超级链接获得。在过去的三个月里,内部人士出售了8,168股公司股票,价值155,402美元。内部人士持有该公司14.90%的股份。
Analyst Ratings Changes
分析师评级发生变化
Imago BioSciences Price Performance
Imago BioSciences性价比
NASDAQ IMGO opened at $16.77 on Friday. Imago BioSciences, Inc. has a 12 month low of $11.56 and a 12 month high of $30.21. The stock's fifty day moving average price is $16.32 and its 200-day moving average price is $17.09.
纳斯达克IMGO上周五开盘报16.77美元。Imago BioSciences,Inc.的12个月低点为11.56美元,12个月高位为30.21美元。该股的50日移动均线价格为16.32美元,200日移动均线价格为17.09美元。
About Imago BioSciences
关于Imago BioSciences
(Get Rating)
(获取评级)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
临床阶段生物制药公司Imago BioSciences,Inc.发现和开发了针对赖氨酸特异性脱甲基酶1(LSD1)的小分子产品候选产品,LSD1是一种用于生产骨髓中血细胞的酶。它的主要候选产品是Bomedemstat,正在进行第二阶段临床试验,用于治疗骨髓增生性肿瘤和慢性骨髓癌,如骨髓纤维化、原发性血小板增多症和真性红细胞增多症。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- 免费获取StockNews.com关于Imago BioSciences(IMGO)的研究报告
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏,这些股票可能表现优异
- DocuSign是否即将发生重大逆转?
- 石油和天然气股票:投资可再生能源的安全途径
- 这些绿色能源公司适合你的投资组合吗?
Want to see what other hedge funds are holding IMGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating).
想看看其他对冲基金持有IMGO的股票吗?访问HoldingsChannel.com获取Imago BioSciences,Inc.(纳斯达克代码:IMGO-GET Rating)的最新13F申报文件和内幕交易信息。
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Imago BioSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧